Miransertib - ArQule

Drug Profile

Miransertib - ArQule

Alternative Names: ARQ-092; Miransertib

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ArQule; Daiichi Sankyo Company
  • Developer ArQule; National Human Genome Research Institute
  • Class Antineoplastics; Cyclobutanes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Proteus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Growth disorders; Proteus syndrome
  • Phase I Solid tumours
  • Preclinical Congenital heart defects; Sickle cell anaemia

Most Recent Events

  • 20 Nov 2017 Chemical structure information added
  • 01 Nov 2017 The US FDA granted Rare Pediatric Disease Designation for miransertib in Proteus syndrome
  • 23 Oct 2017 AeQule initiates an expanded-access programme for Proteus syndrome and Growth disorders (In children, In adolescents, In adults, In the elderly) (NCT03317366)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top